- Home
- PRQR vs MREO Comparison
PRQR vs MREO Comparison
Compare PRQR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | MREO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Netherlands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 286.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | MREO |
|---|---|---|
| Price | $2.34 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $8.14 | $7.40 |
| AVG Volume (30 Days) | 348.1K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,859,556.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $72.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $1.47 |
| 52 Week High | $3.97 | $3.94 |
Technical Indicators
Market Signals| Indicator | PRQR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 52.47 |
| Support Level | $2.10 | $1.75 |
| Resistance Level | $2.40 | $1.87 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 89.49 | 69.44 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).